Explorer les evidences

1 sensitivityDetectable HBV-DNA at baseline had sensitivity of 1.00 and specificity of 0.80 for predicting HBsAg seroclearance.

Côte d'Ivoirehépatite Bpublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

33,3 %Among 66 HBsAg-positive patients, 33.3% were inactive HBV carriers.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

13,4 %HBsAg prevalence was 13.4% among 491 adult HIV patients in Abidjan.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

13,2 per_100_person_yearsAfter a median 2.0 year follow-up, the incidence rate of serious HIV-related events was 13.2 per 100 person-years among HIV-HBV co-infected patients.

Côte d'Ivoirehépatite B · VIH/sidapublié 2017The American journal of tropical medicine and hygieneeurope_pmcdocument de 7 observationsDOI 10.4269/ajtmh.16-1016

86,6 %Cumulative proportion of undetectable HBV-DNA was 86.6% in patients with baseline pcG1896A mutation and 66.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

7,3 %HBsAg positivity prevalence among first-time female blood donors in Abidjan was 7.3% in 1992–1994 and 7.1% in 2010–2012.

Côte d'Ivoirehépatite Bobservé 1992–1994publié 2018Open forum infectious diseaseseurope_pmcdocument de 12 observations

75,2 %Among 161 antiretroviral-naïve HIV-HBV coinfected patients in Côte d'Ivoire, 121 (75.2%) had detectable HBV DNA.

Côte d'Ivoirehépatite B · VIH/sidapublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

23 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 23% had never been exposed to HBV.

Côte d'Ivoirehépatite B · VIH/sidapublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

42 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 42% had isolated anti-HBc.

Côte d'Ivoirehépatite B · VIH/sidapublié 2010Antiviral therapyeurope_pmcdocument de 7 observations

21,3 %Occult HBV infection prevalence was 21.3% among HBsAg-negative, anti-HBcAb-positive, anti-HBsAb-negative patients with detectable HBV DNA.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

6,6 %The overall cumulative proportion of HBsAg seroclearance was 6.6% (n = 10).

Côte d'Ivoirehépatite Bpublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

98,9 %Among 93 patients tested, 92 (98.9%) harbored HBV genotype E.

Côte d'Ivoirehépatite Bpublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

8,5 %Among 791 HIV-infected patients in West Africa, 67 (8.5%) were HBsAg positive.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2012publié 2017BMC infectious diseaseseurope_pmcdocument de 7 observations

4,37 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 4.37 (95% CI = 0.98–13.02) at CD4+ counts 351–500/mm³ compared to HBsAg-negative individuals.

Côte d'Ivoirehépatite B · VIH/sidapublié 2021Antiviral therapyeurope_pmcdocument de 4 observations

20,5 %Among 161 antiretroviral-naïve HIV-HBV coinfected patients in Côte d'Ivoire, 33 (20.5%) were HBeAg positive.

Côte d'Ivoirehépatite B · VIH/sidapublié 2016Journal of gastroenterology and hepatologyeurope_pmcdocument de 11 observationsDOI 10.1111/jgh.13156

51,1 %Only 51.1% of the AEB victims were correctly vaccinated against hepatitis B.

Côte d'Ivoirehépatite Bobservé January 2000 to December 2005publié 2007Medecine et maladies infectieuseseurope_pmcdocument de 11 observations

10,8 %HBsAg positivity prevalence among first-time blood donors in Abidjan remained stable at 10.8% in 1992–1994 and 11.1% in 2010–2012.

Côte d'Ivoirehépatite Bobservé 1992–1994publié 2018Open forum infectious diseaseseurope_pmcdocument de 12 observations

97,7 %97.7% of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire harboured HBV genotype E at ARV-initiation.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

30,3 %Among 66 HBsAg-positive patients, 30.3% had HBeAg-negative hepatitis.

Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations

0 seroconversionsNo HIV and HBV seroconversion was observed after a 3-month follow-up among rape victims receiving antiretroviral chemoprophylaxis in Abidjan.

Côte d'Ivoirehépatite B · VIH/sidapublié 2015Medecine et maladies infectieuseseurope_pmcdocument de 3 observations

0 %Cumulative proportion of HBsAg seroclearance was 0% in patients with baseline pcG1896A mutation and 36.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

59,3 %Baseline pcG1896A mutation was identified in 51 (59.3%) of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

25 monthsThe median follow-up duration was 25 months (interquartile range 19–31 months) among HBeAg-negative HIV/HBV co-infected patients in Côte d'Ivoire.

Côte d'Ivoirehépatite B · VIH/sidapublié 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument de 4 observations

10 000 copies/mLChronic HBeAg-negative HBV infection phase was defined as HBV DNA ≤10,000 copies/mL and normal alanine aminotransferase (ALT).

Côte d'Ivoirehépatite Bpublié 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument de 4 observations

135 individualsAmong 190 HBsAg-positive participants, 135 (71%) had HBV DNA+.

Côte d'Ivoirehépatite Bpublié 2021Antiviral therapyeurope_pmcdocument de 4 observations